Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1
2024-518144-20-00Phase 2Authorised
- Sponsor
- Arbor Biotechnologies
- Start
- May 2025
- Modality
- Gene Therapies
- Countries
- 8
01
Overview
Phase 2, open-label trial of ABO-101 in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Arbor Biotechnologies. Primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs), including ABO-101-related TEAEs and serious adverse events (SAEs). Planned start May 2025; status: authorised.
02
Drugs
ABO-101
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on 2024-518144-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518144-20-00.